Inferring tumour purity and stromal and immune cell admixture from expression data
By K. Yoshihara, Maria Shahmoradgoli, Emmanuel Martinez, Rahulsimham Vegesna, Hoon Kim, Wandaliz Torres-García, V. Treviño, Hui Shen, Peter W. Laird, D. Levine and 5 more. Nature Communications, 2013
7,904 citations recorded by the source corpus.
Infiltrating stromal and immune cells form the major fraction of normal cells in tumour tissue and not only perturb the tumour signal in molecular studies but also have an important role in cancer biology. Here we describe ‘Estimation of STromal and Immune cells in MAlignant Tumours using Expression data’ (ESTIMATE)—a method that uses gene expression signatures to infer the fraction of stromal and immune cells in tumour samples. ESTIMATE scores correlate with DNA copy number-based tumour purity across samples from 11 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing and available through The Cancer Genome Atlas. The prediction accuracy is further corroborated using 3,809 transcriptional profiles available elsewhere in the public domain. The ESTIMATE method allows consideration of tumour-associated normal cells in genomic and transcriptomic studies. An R-library is available on https://sourceforge.net/projects/estimateproject/. Tumour biopsies contain contaminating normal cells and these can influence the analysis of tumour samples. In this study, Yoshihara et al.develop an algorithm based on gene expression profiles from The Cancer Genome Atlas to estimate the number of contaminating normal cells in tumour samples.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/282950d8fd6fbee7b80421ff48c5d20c7af9925f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- W.J. Greenleaf
- Ansuman T. Satpathy
- Gad Getz
- R. DePinho
- W. Marston Linehan
- Christopher Sander
- Tiago C. Silva
- James P. Allison
In Oncology
- Padmanee Sharma
- C. Sautès-Fridman
- James P. Allison
- John N. Weinstein
- Christopher Sander
- Peter W. Laird
- Gad Getz
- J. Bellmunt
In Pulmonary and Respiratory Medicine
Citations in the corpus
- The chromatin accessibility landscape of primary human cancers (2018, background): “The accessibility of these peak-to-gene links that were predicted to be immune-related is highly correlated with computationally predicted metrics of immune infiltration (46, 47) and inversely correlated with tumor purity (48) (Fig.”
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma (2017, methodology): “Analysis of immune populations by ESTIMATE revealed that both Clusters 2 and 3 displayed immune cell infiltration (Supplementary Fig.”
- Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures (2019, positive): “Moreover, the abundance of immune cells and other cells in the TME can be estimated using computational methods (16-18).”
- Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression (2016, methodology): “MCP-counter is more sensitive and specific in the interpretation of its scores than other previously published TMbased methods [11, 12] as a result of the rigorous, unbiased, and conservative approach to define the TM sets on which it is based (Fig.”
- Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma (2020, background): “ESTIMATE immune scores (Yoshihara et al., 2013), reduced for all STK11 mutants, were particularly low for those WT forKRAS (Figure 5D; Table S5).”
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer (2015, methodology): “The cutoff line for positive expression was determined as reported previously (Yoshihara et al, 2013).”
- A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies (2017, positive): “As with the analogous tools developed for mRNA expression data [10, 11], these algorithms can be classified as either “referencefree” [6, 8] or “reference-based” [5], depending on whether they use an a-priori database of cell-type * Correspondence: a.”
- Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer (2017, neutral): “To further delineate the identity of carcinoma and non-carcinoma cells, we analysed the expression of tumour-associated stromal or immune gene sets proposed in the tumour purity estimation, ESTIMATE 26 .”
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab (2017, methodology): “REAGENT or RESOURCE SOURCE IDENTIFIER ESTIMATE Yoshihara et al., 2013; PMID: 24113773 http://bioinformatics.mdanderson.org/main/ESTIMATE: Overview FACETS v0.”
- New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx (2019, methodology): “To account for tumor purity in the TCGAbiolinks workflow, we designed the TCGAtumor_purity function that filters data according to one of the following five methods: i) ESTIMATE (Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data) [49]; ii) ABSOLUTE to infer tumo”
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features (2017, neutral): “Variable Training set (n=225) Validation Set (n=131) TCGA set (n=190) Median age (IQR) 66 (61-72) 66 (55-71) 62 (52-70) Gender, male (%) 178 (79) 96 (73) 123 (65) Etiology (%) Hepatitis C 101 (46) 64 (50) N/A Hepatitis B 48 (21) 39 (30) N/A Alcohol 33 (15) 6 (5) N/A Others 38 (17) 19 (15) Child-Pugh”
- IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures (2020, methodology): “ESTEMATE dissects non-malignant contextures, including stromal and immune signatures, to determine tumor purity (13).”